Bożena Karolko

Bożena Karolko

Auto-generated profile, based on publicly available information

Bożena Karolko

Institute of Heart Diseases, Wroclaw Medical University, Poland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Thrombosis Research
Verified
Journal Article
Closed access
IPIzabela Pawlaczyk
Izabela Pawlaczyk
LCLeszek Czerchawski
Leszek Czerchawski
WKWiktor Kuliczkowski
Wiktor Kuliczkowski
BKBożena Karolko
Bożena Karolko
WPWitold Pilecki
Witold Pilecki
RGRoman Gancarz
Roman Gancarz

1 February 2016 in JACC
Verified
Journal Article
Closed access
WKWojciech Kosmala
Wojciech Kosmala
ARAleksandra Rojek
Aleksandra Rojek
MPMonika Przewlocka-Kosmala
Monika Przewlocka-Kosmala
AMAndrzej Mysiak
Andrzej Mysiak
BKBozena Karolko
Bozena Karolko
TMThomas H. Marwick
Thomas H. Marwick

11 August 2018 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
TKT. Kotwica
T. Kotwica
JRJ. Relewicz
J. Relewicz
ARA. Rojek
A. Rojek
MTM. Tupikowska‐Marzec
M. Tupikowska‐Marzec
MKM. Kabaj
M. Kabaj
MPM. Przewlocka‐Kosmala
M. Przewlocka‐Kosmala

31 December 2007 in Thrombosis Research
Verified
Journal Article
Closed access
PDF file
WKWiktor Kuliczkowski
Wiktor Kuliczkowski
MKMalgorzata Kobusiak-Prokopowicz
Malgorzata Kobusiak-Prokopowicz
IPIwona Prajs
Iwona Prajs
BKBozena Karolko
Bozena Karolko
WMWalentyna Mazurek
Walentyna Mazurek

25 April 2022 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
BKBożena Karolko
Bożena Karolko
ASAdam Serafin
Adam Serafin
MPMonika Przewlocka-Kosmala
Monika Przewlocka-Kosmala
Blood concentration of galectin-3 (Gal-3) - a biomarker of fibrosis useful in diagnostics and prognostication in heart failure (HF) - is known to be elevated in patients with renal impairment, a condition which often accompanies cardiac insufficiency. To investigate the effect of moderately reduced renal function (estimated glomerular filtration rate (eGFR) 30-60 mL/min/1.73 m2) on the diagnostic and prognostic utility of circulating Gal-3 in patients with HF with preserved ejection fraction (HFpEF). Clinical, biochemical and echocardiographic variables were collected at baseline in 154 patients with HFpEF: 101 with normal and 53 with moderately reduced renal function, who were followed up for 48 (24-60) months for HF hospitalization and cardiovascular (CV) death (composite endpoint). Patients with moderately impaired renal function were characterized by higher age, Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, Gal-3, B-type natriuretic peptide (BNP) and New York Heart Association (NYHA) class, lower hemoglobin, and more advanced left ventricular diastolic dysfunction. Older age, female sex and deeper impairment of renal performance were determinants of higher Gal-3 blood concentrations. Lower exercise capacity (lower peak VO2) was associated with higher Gal-3 level and more pronounced renal impairment. Multivariable regression analysis demonstrated the significance of renal dysfunction as a determinant of lower exercise capacity and revealed a significant interaction between Gal-3 and eGFR with respect to peak VO2. The addition of Gal-3 to the prognostic models based on clinical data improved their predictive power for the study endpoint. The Kaplan-Meier analysis revealed that the presence of moderately reduced renal function with eGFR 30-60 mL/min/1.73 m2 did not enhance the increased risk of adverse outcome associated with Gal-3 above the median. In patients with HFpEF, the coexistence of moderate renal dysfunction does not deteriorate the prognostic usefulness of circulating Gal-3. However, renal impairment modifies the association between Gal-3 and exercise capacity, which supports the need to adjust for kidney function when interpreting the contribution of Gal-3 to exercise intolerance in this population.

31 July 2010 in Thrombosis Research
Verified
Journal Article
Closed access
WKWiktor Kuliczkowski
Wiktor Kuliczkowski
AFA. Filus
A. Filus
JKJ. Kuliczkowska-Plaksej
J. Kuliczkowska-Plaksej
ATA. Trzmiel-Bira
A. Trzmiel-Bira
LLLukasz Laczmanski
Lukasz Laczmanski
AMA. Milewicz
A. Milewicz